Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Meiosis II01:57

Meiosis II

Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each containing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ovarian stimulation with follitropin δ is safe and effective: results from the RITA randomized, double-blind, placebo-controlled trials.

Fertility and sterility·2026
Same author

Maternal exposure to fine particulate matter and pregnancy outcomes in women undergoing <i>in vitro</i> fertilization: A multicenter retrospective study.

Eco-Environment & Health·2026
Same author

Melatonin enhances vitrified mouse blastocyst development by mitigating oxidative stress and preserving mitochondrial function.

Molecular human reproduction·2025
Same author

Ovarian stimulation with follitropin delta is safe and effective: results from the RITA randomized, double-blind, placebo-controlled trials.

Fertility and sterility·2025
Same author

Identification and Validation of RPL7 and RCCD1 as Potential Biomarkers Associated with Immune Infiltration in Patients with Thin Endometrium.

Reproductive sciences (Thousand Oaks, Calif.)·2025
Same author

Condensate-forming eIF4ET ensures adequate levels of meiotic proteins to support oocyte storage.

Life science alliance·2025
Same journal

More Than Cycles: Rethinking Cancer Surveillance in PMOS.

Fertility and sterility·2026
Same journal

Fresh vs. frozen donor oocytes: which strategy best serves patients in contemporary assisted reproductive technology?

Fertility and sterility·2026
Same journal

From fetal life to adulthood: cardiometabolic health of offspring conceived by assisted reproductive technologies, a systematic review.

Fertility and sterility·2026
Same journal

Uterus-Sparing Laparoscopic Reversal of Complete Non-Puerperal uterine Inversion: A rare Case and Challenging Procedure!

Fertility and sterility·2026
Same journal

Minimally Invasive, Fertility-Sparing Surgical Management of Multiple Bilateral Ovarian Dermoid Cysts.

Fertility and sterility·2026
Same journal

Preconception dietary patterns in association with live birth and pregnancy loss: a couples-based approach.

Fertility and sterility·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Whole Ovary Immunofluorescence, Clearing, and Multiphoton Microscopy for Quantitative 3D Analysis of the Developing Ovarian Reserve in Mouse
12:36

Whole Ovary Immunofluorescence, Clearing, and Multiphoton Microscopy for Quantitative 3D Analysis of the Developing Ovarian Reserve in Mouse

Published on: September 3, 2021

Repetitive oocyte donation does not decrease serum anti-Müllerian hormone levels.

Orhan Bukulmez1, Qin Li, Bruce R Carr

  • 1Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida 32610-0294, USA. obukulmez@ufl.edu

Fertility and Sterility
|July 28, 2009
PubMed
Summary
This summary is machine-generated.

Anti-Müllerian hormone (AMH) levels in oocyte donors do not decrease with repetitive donation cycles. This suggests that oocyte donation may not accelerate ovarian aging in women.

More Related Videos

Collection of Human Follicular Fluid, Follicle Somatic Cells, and Immature Oocytes from Individuals Undergoing In Vitro Fertilization
06:40

Collection of Human Follicular Fluid, Follicle Somatic Cells, and Immature Oocytes from Individuals Undergoing In Vitro Fertilization

Published on: October 24, 2025

Related Experiment Videos

Last Updated: Jun 21, 2026

Whole Ovary Immunofluorescence, Clearing, and Multiphoton Microscopy for Quantitative 3D Analysis of the Developing Ovarian Reserve in Mouse
12:36

Whole Ovary Immunofluorescence, Clearing, and Multiphoton Microscopy for Quantitative 3D Analysis of the Developing Ovarian Reserve in Mouse

Published on: September 3, 2021

Collection of Human Follicular Fluid, Follicle Somatic Cells, and Immature Oocytes from Individuals Undergoing In Vitro Fertilization
06:40

Collection of Human Follicular Fluid, Follicle Somatic Cells, and Immature Oocytes from Individuals Undergoing In Vitro Fertilization

Published on: October 24, 2025

Area of Science:

  • Reproductive Endocrinology
  • Ovarian Physiology
  • Assisted Reproductive Technologies

Background:

  • Anti-Müllerian hormone (AMH) is a key indicator of ovarian reserve and aging.
  • Repetitive oocyte donation involves multiple cycles of ovarian stimulation and oocyte retrieval.
  • The impact of repeated oocyte donation on ovarian reserve markers like AMH requires investigation.

Purpose of the Study:

  • To investigate the longitudinal changes in serum AMH levels among women undergoing repetitive oocyte donation.
  • To determine if repeated oocyte donation cycles are associated with accelerated ovarian aging.

Main Methods:

  • Retrospective cohort study of 36 young women undergoing 3-7 oocyte donation cycles.
  • Serum AMH levels were measured during each treatment cycle.
  • Longitudinal trends and intercycle variations in AMH were analyzed.

Main Results:

  • Serum AMH levels did not demonstrate a decrease with an increasing number of oocyte donation cycles.
  • AMH was a predictor of oocyte yield in initial cycles and negatively associated with donor age and FSH dose.
  • No significant changes in clinical outcomes (FSH dose/oocyte ratio) were observed over repetitive cycles.

Conclusions:

  • Repetitive oocyte donation does not appear to cause a decrease in serum AMH levels.
  • These findings suggest that oocyte donation may not lead to accelerated ovarian aging.
  • Ovarian reserve markers remain stable in oocyte donors over multiple donation cycles.